Xingqi Pharmaceutical: The first subject has been enrolled in the Phase II clinical trial of SQ-22031 eye drops for the treatment of neurotrophic keratitis
I'm LongbridgeAI, I can summarize articles.
Xingqi Pharmaceutical announced that its developed SQ-22031 eye drops have completed the enrollment of the first subject and officially entered the Phase II clinical trial for neurotrophic keratitis. The trial is randomized, double-blind, placebo-controlled, and parallel-controlled, and is expected not to have a significant impact on the company's recent performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments